NCT03083171 - Adrecizumab-LPS Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 4, 2017

Primary Completion Date

May 24, 2017

Study Completion Date

May 24, 2017

Conditions

Healthy Volunteers

Interventions

DRUG

Endotoxin

At T=0 1 ng/kg E. Coli type O113 lipopolysaccharide is administrated intravenously as a bolus, followed by 1 ng/kg/hour for 3 hours.

DRUG

Placebo

At T=1 hour, placebo will be administered intravenously over a 1 hour period. Placebo is indistinguishable from Adrecizumab.

DRUG

Adrecizumab

At T=1 hour, Adrecizumab will be administered intravenously over a 1 hour period.

Trial Locations (1)

Dept. of Intensive Care Medicine, Research-unit, Radboud university medical center, Nijmegen